Acute inflammation of the pancreas is associated with abdominal pain. Depending on its severity, it may also be associated with mild, nonspecific, self-limiting clinical signs, or signs referable to cardiovascular shock, disseminated intravascular coagulation (DIC), or multiorgan failure. For an overview of the pathogenesis and diagnosis of acute pancreatitis in dogs, please see “Diagnosis of Acute Pancreatitis in Dogs” in the January/February 2020 issue.

Given that the pathogenesis of acute pancreatitis is a complex, self-perpetuating, autodigestive process, it is difficult to predict whether patients will have mild or rapidly progressive disease. Patients with subclinical and milder forms of pancreatitis may display mild, nonspecific clinical signs such as lethargy and intermittent anorexia, and often the diagnosis in these patients is missed. When pancreatitis is suspected, these patients are often treated as outpatients with antiemetics (e.g., maropitant), subcutaneous fluids, and a low-fat diet. More severe forms of pancreatitis require aggressive supportive care and intensive hospitalization, with treatment including analgesia, nutritional management, antiemetics, gastrointestinal acid suppression, and correction of fluid, electrolyte, and acid-base abnormalities.

This article addresses the major aspects of management of severe acute pancreatitis. Recommendations are based on published supporting evidence when such evidence exists; however, when objective data to support current recommendations are lacking, they are based on published standard of care guidelines, anecdotal evidence, and clinical experience.

**ANALGESIA**

Dogs with pancreatitis have local and visceral pain. Pain scoring systems are routinely used to assess the severity of pain and determine analgesic plans; however, analgesic agents have not been evaluated in dogs with acute pancreatitis.1

At the author’s institution, a multifaceted, individualized approach to analgesia is based on...
the patient’s level of pain as determined by the use of behavioral and physiologic pain scoring systems. The initial choice of analgesic agent is an opioid (full or partial µ agonist). Then, depending on the severity of pain, an NMDA (N-methyl-D-aspartate) antagonist (e.g., ketamine) and/or a local anesthetic agent (e.g., lidocaine) may be added adjunctively as intravenous constant-rate infusions.

Ketamine is the first choice when animals continue to be subjectively unsettled or look uncomfortable after opioid administration. Signs of continued pain may include vocalization/crying, failure to respond or interact with people, and guarding, vocalizing, or pulling away when the abdomen is palpated. Ketamine plays a role in reduction of central sensitization and may help reduce nociception from intra-abdominal organs and visceral peritoneum.¹

For animals with continued refractory behavioral and physiologic signs of pain, lidocaine may be added to the medical therapy (TABLE 1). Lidocaine not only exerts analgesic effects, but also has been shown to improve gastrointestinal function and anti-inflammatory properties.¹ Once patients are eating, they are usually transitioned to oral medications like tramadol and/or gabapentin (TABLE 1). Nonsteroidal anti-inflammatory drugs (NSAIDs) are not recommended owing to the presence of hypovolemia and dehydration in most dogs with severe acute pancreatitis.¹

**NUTRITIONAL MANAGEMENT**

Historically, it has been advocated to “rest” the pancreas during bouts of acute pancreatitis by withholding enteral nutrition to avoid stimulation of the exocrine pancreas and the risk for continued premature zymogen activation.³⁻⁶ Supporting evidence for this practice is minimal, and several studies challenge it.⁶ Evidence is mounting that early enteral nutrition improves clinical outcomes in systemically ill patients.⁵⁻⁷⁻⁸ Specifically, early enteral nutrition has been shown to decrease ileus and inflammation, stimulate intestinal mucosal regeneration and mucosal blood flow, decrease protein catabolism, and prevent protein-energy malnutrition.⁶⁻⁸ A recent retrospective study of 34 dogs with acute pancreatitis concluded that early enteral nutrition (i.e., within 48 hours of hospitalization) had a positive effect on return to voluntary food intake, was associated with less gastrointestinal intolerance, and should be considered as part of medical management.⁴

Imposed anorexia may be counterproductive to overall gastrointestinal health, as avoidance of enteral nutrition has been correlated with increased gastrointestinal permeability, bacterial or endotoxin translocation, and immunosuppression.³⁻⁶⁻¹⁰ Increased metabolic demands, protein catabolism, and bacterial translocation associated with pancreatitis itself may lead to systemic inflammatory response syndrome (SIRS).¹⁰

<table>
<thead>
<tr>
<th>DRUG</th>
<th>DOSE</th>
<th>MODE OF ACTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methadone</td>
<td>0.1–1 mg/kg IV, IM, SC</td>
<td>µ receptor agonist</td>
</tr>
<tr>
<td>Fentanyl</td>
<td>0.2–0.8 mcg/kg/min CRI</td>
<td>µ receptor agonist</td>
</tr>
<tr>
<td>Ketamine</td>
<td>5–20 mcg/kg/min CRI</td>
<td>NMDA receptor antagonist</td>
</tr>
<tr>
<td>Lidocaine</td>
<td>25–50 mcg/kg/min CRI</td>
<td>Local anesthetic (voltage-gated sodium channel blocker)</td>
</tr>
<tr>
<td>Buprenorphine</td>
<td>10–40 mcg/kg IV, IM</td>
<td>Partial µ receptor agonist</td>
</tr>
<tr>
<td>Tramadol</td>
<td>5 mg/kg PO</td>
<td>Weak µ agonist Inhibits monoamine transporters (noradrenaline and serotonin)</td>
</tr>
<tr>
<td>Gabapentin</td>
<td>10–20 mg/kg PO</td>
<td>Dorsal horn excitatory neurotransmitter inhibitor (e.g., substance P, calcitonin gene-related peptide)</td>
</tr>
<tr>
<td>Maropitant</td>
<td>1 mg/kg IV, SC</td>
<td>NK₁ receptor antagonist</td>
</tr>
<tr>
<td>Ondansetron</td>
<td>0.5–1 mg/kg IV, SC</td>
<td>5-HT₃ antagonist</td>
</tr>
<tr>
<td>Famotidine</td>
<td>0.5–1 mg/kg IV, SC</td>
<td>Histamine receptor antagonist</td>
</tr>
<tr>
<td>Omeprazole/ pantoprazole/lansoprazole</td>
<td>1 mg/kg IV</td>
<td>Proton pump inhibitors</td>
</tr>
</tbody>
</table>

⁵-HT₃=5-hydroxytryptamine; CRI=constant-rate infusion; IM=intramuscular; IV=intravenous; NK₁=neurokinin-1; NMDA=N-methyl-D-aspartate; PO=oral; SC=subcutaneous.
At the author’s hospital, nasoesophageal and nasogastric tubes are often used in management of patients with acute pancreatitis. Placement of a feeding tube is relatively inexpensive and generally well tolerated. Syringe feeding is not recommended based on its practical inability to deliver full nutrient requirements and the risk of food aversion and aspiration.5

Ideally, hospitalized dogs should be fed their estimated resting energy requirement (RER) based on either $70 \times (\text{body weight in kg})^{0.75} = \text{RER (kcal/day)}$ or $[30 \times (\text{body weight in kg})] + 70 = \text{RER (kcal/day)}$. The first formula is the more accurate of the two and is used at the author’s institution for dogs weighing <5 kg or >25 kg, while the second is an approximation of RER for dogs weighing 5 to 25 kg.1,5 In patients that cannot tolerate their full RER as enteral nutrition, providing at least part of the RER via this route will likely provide some benefit in maintaining the absorptive surface area of the intestines.5

Liquid enteral diets designed for veterinary use are available (TABLE 2). Human enteral diets may be used for short-term feeding, but their lower fat, protein, and essential nutrient profiles make them inappropriate for long-term use.3

**ANTIEMETICS**

Vomiting and nausea-associated inappetence are common in patients with acute pancreatitis, and antiemetics are commonly used for their management. These signs are likely to be mediated centrally by circulating emetic agents and peripherally by ileus, peritonitis, and pancreatic destruction.3 Several antiemetics are routinely used for management and are considered effective and useful, although few have been subjected to rigorous testing;11 common choices are listed in TABLE 1.

Maropitant, an NK1 (neurokinin-1) receptor antagonist, is a first-line antiemetic that acts both centrally (i.e., chemoreceptor trigger zone and vomiting center) and peripherally (gastrointestinal tract).1,3,12,15 Maropitant has been found to be superior to metoclopramide for management of peripherally stimulated vomiting.13 Rodent studies have suggested that, in addition to its antiemetic action, maropitant may inhibit inflammation by blocking NK1 receptors in the pancreas.12,14 Other antiemetic agents with proposed anti-inflammatory activity, such as serotonergic antagonists (e.g., ondansetron), can be added as necessary to improve nausea and control emesis.1

At the author’s institution, maropitant is the preferred antiemetic. For dogs that are refractory to this medication, metoclopramide (1 to 2 mg/kg q24h as a constant-rate infusion) or ondansetron (0.1 to 1.0 mg/kg q6h to q12h) is used as additional supportive therapy.

**GASTRIC ACID SUPPRESSION**

Proton pump inhibitors (e.g., omeprazole, pantoprazole) and histamine type-2 (H2) receptor antagonists (e.g., famotidine, ranitidine) are useful adjunctive medications and may decrease the risk of gastric or intestinal ulceration or esophagitis (TABLE 1).

Reduction of gastric acidity is frequently recommended during treatment for acute pancreatitis, although no evidence is available that shows reduction of gastric acidity leads to decreased pancreatic exocrine stimulation or improved outcome in dogs with acute pancreatitis.1,3,15 However, if there is clinical evidence of gastric ulceration (hematemesis or melena) or esophagitis (repeated eructation, regurgitation), then gastric acid suppression is indicated.1

When used twice a day, proton pump inhibitors are superior to H2-antagonists for raising the intragastric

---

**TABLE 2 Fat Content and Energy Density of Selected Liquid Diets**

<table>
<thead>
<tr>
<th>DIET</th>
<th>PROTEIN (G/1000 KCAL)</th>
<th>FAT (G/1000 KCAL)</th>
<th>KCAL/ML</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ensure Plus abbottnutrition.com</td>
<td>37</td>
<td>31</td>
<td>1.5</td>
</tr>
<tr>
<td>Gastrointestinal Low-fat Liquid royalcanin.com/us</td>
<td>90</td>
<td>20</td>
<td>1</td>
</tr>
<tr>
<td>Jevity abbottnutrition.com</td>
<td>42</td>
<td>33</td>
<td>1.5</td>
</tr>
<tr>
<td>Vivonex nestlehealthscience.us</td>
<td>50</td>
<td>12</td>
<td>1</td>
</tr>
</tbody>
</table>
pH. No greater effect is exhibited with the
short-term combination of H2-antagonists and proton
pump inhibitors compared with use of either drug
class alone.

**INTRAVENOUS FLUID THERAPY**

A disturbance in pancreatic microcirculation plays a
central role in the pathogenesis of acute pancreatitis
and the transformation from acute, self-limiting to
severe, necrotizing pancreatitis. The pancreatic
microcirculation can be disturbed by many factors,
including hypovolemia, dehydration, increased
capillary permeability, and microthrombi.

The rationale for intravenous fluid therapy is to
replenish blood volume and thus blood flow to the
pancreas, with several animal studies demonstrating
both improved pancreatic circulation and survival with
fluid resuscitation. However, pancreatic blood flow
and oxygen consumption are not completely restored
with fluid resuscitation alone. Fluid plan should incorporate the estimated fluid
deficit, any ongoing losses (i.e., vomiting, diarrhea),
and the ongoing maintenance requirement. Electrolytes
should be monitored and supplemented accordingly.

Crystalloid therapy alone may not be adequate in dogs
with severe acute pancreatitis. Colloid fluid
administration has been studied in people with
pancreatitis, with improved outcomes found compared
with crystalloid resuscitation. The current role of
colloid solutions in pancreatitis management in
veterinary patients is controversial. Several human
studies and a recent veterinary study have suggested
that there is an increased risk of renal dysfunction,
coagulation/platelet dysfunction, and mortality with
the use of colloids. Additional prospective
longitudinal studies in veterinary medicine are
warranted to investigate the increased risks (e.g., acute
kidney injury) associated with colloid administration in
critically ill patients.

**OTHER THERAPIES**

**Plasma Transfusion**

There is also little information regarding the use of
plasma in acute pancreatitis. Purported benefits of
plasma transfusions include correction of
hypoalbuminemia and replacement of circulating
antiproteases (e.g., α-macroglobulins, antitrypsins),
coagulation factors, and anti-inflammatory factors.
A single retrospective study reported the use of plasma
in 77 dogs with acute pancreatitis over a 10-year
period. The study concluded that there was no benefit
to administration of fresh frozen plasma and that until
further evidence is published, plasma transfusions
should be reserved for pancreatitis patients with
documented coagulopathies. Studies of the use of other
blood products in these patients are lacking.

**Glucocorticoids**

Historically, the use of glucocorticoids has been
avoided in dogs with acute pancreatitis. However, there is currently no
consensus with regard to their use or optimum timing/dose in patients with pancreatitis.

Glucocorticoids counteract nearly all pathways of
inflammation. In pancreatitis, they have been shown to enhance apoptosis and increase the production of
pancreatitis-associated proteins, which confer a
protective effect against pancreatic inflammation. A
recent clinical study demonstrated that dogs receiving prednisolone 1 mg/kg/day had a greater decrease in
C-reactive protein concentration, fewer days until
clinical improvement, shorter hospitalization periods,
and better survival. Conclusions from these studies
should be viewed with caution and other facets of
aggressive medical management of pancreatitis should be
maximized before the implementation of glucocorticoid
therapy. Further objective clinical trials are needed to
confirm findings from the most recent studies.

**Antibiotics**

Antibiotic treatment for acute pancreatitis is not
recommended, as pancreatitis is considered to be a
sterile inflammatory process that is often accompanied
by pyrexia and leukocytosis. Indications for the use of
antibiotics include failure to respond to aggressive
supportive care, pancreatic necrosis with secondary
infection/abscessation, or melena and hematochezia
suspected to be caused by bacterial translocation from
the small intestine. When indicated, broad-spectrum
parenteral antibiotics that are effective against
gastrointestinal pathogens (e.g., amoxicillin-
clavulanate) should be considered.
Surgery
Surgical management of severe acute pancreatitis may be necessary when there are persistent evidence of biliary obstruction, failure to respond to aggressive medical management, persistent distant organ complications, or pancreatic abscessation or evidence of infection.28-31 The goal of surgery is to relieve the persistent extrahepatic biliary duct obstruction via cholecystoenterostomy or choledochal tube stenting and resect diseased/devitalized or abscessed tissue. Survival rates for dogs requiring pancreatic resection for pancreatic abscessation are 0% to 56%; for dogs undergoing correction of extrahepatic bile duct obstruction, they are 50% to 80.8%.1,28-30 Cellulitis and septic peritonitis are the most common postoperative complications.28

PROGNOSIS
Assessment of severity of acute pancreatitis in dogs is challenging, and several scoring systems have been proposed to assess disease severity and prognosis.31-33 Unfortunately, they have not been globally accepted as useful. Indicators of severe disease and poor prognosis include SIRS, shock, DIC, thrombocytopenia, prolonged coagulation times, renal azotemia, oliguria or anuria, metabolic acidosis, icterus, elevated transaminases, hyperkalemia, hypocalcemia, hyponatremia, hypo-/hyperglycemia, hypothermia, serum pancreatic lipase >1000 µg/L (via Spec cPL® test [idexx.com]), persistently elevated serial C-reactive protein, and elevated urine trypsinogen activation peptide:creatinine ratio.31,33-35

LONG-TERM FOLLOW-UP
Once dogs are eating well and are clinically stable (i.e., no evidence of lethargy, vomiting, hyporexia) they can be discharged from the hospital.36 At the author’s hospital, oral analgesics (e.g., tramadol, gabapentin) are prescribed for patients being discharged with continued mild abdominal discomfort.

Dietary modification is the most important component in the long-term management of dogs with acute pancreatitis. High-fat diets, abrupt changes in food type and composition, and access to trash or table scraps should be avoided.5,37 It is generally accepted that the fat content of diets should be <30 g/1000 kcal.37 Hyperlipidemic dogs should be fed 14 g of fat per 1000 calories to achieve lower serum triglycerides and cholesterol.5

Recognized complications of acute pancreatitis in dogs include extrahepatic bile duct obstruction, diabetes mellitus and diabetic ketoacidosis, and acute fluid collections (i.e., pancreatic abscess or pseudocyst).1,3,37 Relapses or recurrences of acute pancreatitis may result in the development of chronic pancreatitis, exocrine pancreatic insufficiency (EPI), or diabetes mellitus.38 Extrahepatic bile duct obstruction is a local complication of acute pancreatitis and usually manifests as jaundice within 3 to 7 days after onset of pancreatitis.3 It is the author’s and others’ experience that extrahepatic bile duct obstructions and acute fluid collections spontaneously resolve with time.3,39 If required, percutaneous drainage of acute fluid collections has been previously described.40 This is a relatively safe procedure with few complications.39,41

Diabetes mellitus is a commonly recognized comorbidity in patients with pancreatitis, with β cells likely succumbing to “bystander damage” either from nonspecific inflammation or the triggering of an autoimmune process.32 However, an underlying question remains: “Does canine pancreatitis cause diabetes mellitus or can diabetes mellitus result in pancreatitis?” The exact cause and effect has not been elucidated, with both diseases possibly exacerbating each other.37,42,43

Dogs that develop diabetes mellitus or EPI should be treated by the administration of exogenous insulin with lifestyle recommendations and dietary management or by adding a pancreatic enzyme preparation to food and supplementing with parenteral cobalamin, respectively.5,36

References


